Introduction
New psychoactive substances, including substituted cathinones, are public health and regulatory challenges (Baumann and Volkow, 2016; Griffiths et al., 2013; Spiller et al., 2011) . Some compounds, marketed as "bath salts" or "plant food," have similar activity as the stimulants METH and cocaine or the empathogen MDMA and circumvent legal restrictions of the latter compounds (Iversen et al., 2013) . Adverse physical and neuropsychiatric sequelae include tachycardia, brain swelling, hallucinations and paranoia and can result in death (Miotto, et al. 2013; Prosser and Nelson, 2012; Sykutera et al., 2015) . Herein we report the pharmacology of second-generation substituted cathinones, and two compounds that target monoamine transporters, 5,6-methylenedioxy-2-aminoindane (MDAI) and 4-fluoroamphetamine (4-FA). Substituted cathinones, structurally related to METH and MDMA, have a β -position ketone as do methcathinone (MCAT) (Fig 1) and (-)cathinone, the active ingredient in the psychoactive plant product, khat (Glennon, et al., 1987; Kelly, 2011) . At least ten substituted cathinones are schedule 1 substances, having no therapeutic uses and high potential for abuse (Drug Enforcement Administration, 2016) .
The biochemical pharmacology and behavioral effects of first-generation substituted cathinones have been reported. These include butylone, 4-F MCAT (flephedrone), mephedrone, MCAT, 3,4-methylenedioxypyrovalerone (MDPV), naphyrone, and pyrovalerone, (Baumann et al., 2012; Cameron, et al. 2013; Eshleman et al., 2013; Gatch et al., 2013; Hadlock et al., 2011; Iversen et al., 2013; Lopez-Arnau et al., 2012; Simmler et al., 2014a) and results are summarized in German et al., (2014) . Their mechanisms of action are similar, with the compounds primarily binding, with varying affinities and selectivities, to DAT, SERT and NET. Some compounds are transporter blockers, similar to cocaine, while others are substrates, similar to METH. They generally have lower affinities for neurotransmitter receptors than for transporters. 6 Second-generation substituted cathinones are synthesized and available on the internet. 3-Fluoromethcathinone (3-F MCAT) and 4-methylethcathinone (4-MEC) were identified in "plant food" being marketed and used as recreational drugs (Archer, 2009; Caudevilla-Galligo et al., 2013; Odoardi et al., 2016) . Methylenedioxypentedrone (pentylone) and 4-methyl-α-pyrrolidinopropiophenone (4-MePPP) were found in samples of "NRG-1" and "NRG-3" available from websites (Brandt et al., 2011) and pentylone, α -pyrrolidinovalerophenone (α -PVP), 4-MEC, MDAI, 3,4-methylenedioxy-α-pyrrolidinobutiophenone (3,4-MDPBP) and α -methylaminovalerophenone (pentedrone) were confirmed in human blood specimens (Elliott and Evans, 2014; Marinetti and Antonides, 2013) .
Behavioral assays indicate abuse potential of these compounds. 4-MEC, pentedrone, pentylone, 4-MePPP, 3-F MCAT, α -pyrrolidinobutiophenone (α-PBP), and α -PVP stimulate locomotion and substitute, at varying doses, for discriminative stimulus effects of cocaine and METH (Gatch et al., 2015a; Gatch et al., 2015b; Naylor et al., 2015) . 3-F MCAT increases mouse locomotor activity, head weaving and salivation, and decreases rotorod performance (Marusich et al., 2012) . MDAI, an indane analog of MDMA first synthesized in 1990, substitutes for MDMA and cocaine in drug discrimination assays and produces conditioned place preference (Gatch et al., 2016; Nichols, et al. 1990; Oberlender and Nichols, 1991) . In rats, intraperitoneal injections of 4-chloro-methcathinone (4-Cl MCAT) and 4-bromo-methcathinone (Iversen et al., 2013; Rickli et al., 2015; Simmler et al., 2013; Simmler et al., 2014a; Simmler et al., 2014b) . 3,4-MDPPP, 3,4-MDPBP and α -PVP (O-2387) had similar potencies for inhibition of uptake at DAT and NET and much lower potency at SERT (Meltzer et al., 2006; Rickli et al., 2015) . 4-MEC and 4-MePPP have differential effects on DAT and SERT function: both are uptake inhibitors at DAT but inactive at releasing [ 3 H]MPP + via DAT from rat synaptosomes, while at SERT 4-MEC inhibits uptake and stimulates release but 4-MePPP is inactive (Saha et al., 2015) .
The objective of these experiments was to determine and in some cases confirm interactions with monoamine transporters by substituted cathinones that indicate abuse liability. We investigated structure-activity relationship of ten α -pyrrolidinophenones at hDAT, hSERT and hNET and the effect of ortho-and para-substitutions on the phenyl ring of MCAT. We queried if the relationship between binding affinity and potency for inhibition of uptake predicts whether a compound is a transporter inhibitor or substrate. In addition, the relationship between potencies at inhibition of uptake and stimulation of release was assessed.
This article has not been copyedited and formatted. The final version may differ from this version. The methods for characterizing radioligand binding and the functional uptake assays have been described (Eshleman, et al., 1999; Eshleman et al., 2013) . Human embryonic kidney cells stably expressing the recombinant human (h)DAT (HEK-hDAT), hSERT (HEK-hSERT) or hNET (HEK-hNET) were used, with the expression vectors pcDNA1 with pBabepuro for antibiotic resistance (hDAT and hSERT) and pcDNA3 (hNET). Cells were cultured in DMEM supplemented with 5% FetalClone, 5% bovine calf serum, penicillin/streptomycin and 2 µg/ml puromycin (hDAT and hSERT) or 10% FetalClone, penicillin/streptomycin and 300 µg/ml G418.
(hNET Radioactivity remaining on the filter was determined using a Perkin Elmer µbeta-plate reader.
Specific binding was defined as the difference in binding observed in the presence and absence of 5 µM mazindol (HEK-hDAT and HEK-hNET) or 5 µM imipramine (HEK-hSERT).
For [ 3 H]neurotransmitter uptake assays, cells were grown to confluence as described above.
The medium was removed, and cells were washed with cmf-PBS. Cells from each plate were gently scraped and then triturated with a pipette in 3 ml Krebs Hepes. Two cell plates provided enough cells for four concentration-response curves. 1 0 final volume of 500 µl. Specific uptake was defined as the difference in uptake observed in the presence and absence of 5 µM mazindol (HEK-hDAT and HEK-hNET) or 5 µM imipramine (HEK-hSERT). Filtration using a Tomtec 96-well cell harvester through Filtermat A filters presoaked in 0.05% polyethylenimine was used to terminate uptake after 10 min.
Biogenic amine transporters: [ 3 H]Neurotransmitter release
The methods for characterizing drug-induced release of pre-loaded [ 3 H]neurotransmitter from HEK-hDAT, HEK-hSERT and HEK-hNET cells have been described previously (Gatch, et al., 2011; min (11 x 2 min fractions) of effluent were collected. To release the remaining radioactivity in the cells, SDS (1%) was perfused, and 4 fractions, 2.5 min each, were collected. Radioactivity in the samples was determined using conventional liquid scintillation spectrometry.
Data analysis
This article has not been copyedited and formatted. The final version may differ from this version. For release assays, fractional release was defined as the amount of radioactivity in a fraction divided by the total radioactivity remaining in the sample, which was determined by summing the cpms in that fraction and all later fractions. For each time course, the area under the curve (AUC) was calculated using GraphPad Prism with baseline defined as the average of the two lowest fractions of that time course. For each experiment, the AUC of basal release in the absence of drug was subtracted from each AUC before normalizing to the percent of maximal METH-stimulated release (or maximal PCA-stimulated release for some hSERT experiments).
For functional assays, GraphPAD Prism was used to calculate either IC 50 (uptake) or EC 50 (Table 1) . A similar structure-activity relationship was seen when measuring drug potency for inhibition of 1 3
The α -pyrrolidinophenones had lower affinity for hNET than for hDAT, and there was a trend for affinity to increase with increasing chain length, with the 3-carbon α -PVP having the highest affinity. Substitutions at the 4 position or addition of a 3,4-methylenedioxy group either had no effect or decreased potency in the [ 3 H[NE uptake assay.
In general, the α -pyrrolidinophenones had very low affinity for and potency at hSERT ( Table 1) .
As with hDAT, the affinity increased with the length of carbon chain: (Table 1) Pentedrone is structurally similar to α -PVP, with the pyrrolidine moiety replaced by a secondary nitrogen with a methyl group. Pentedrone has lower affinity and potency at hDAT and hNET, but higher affinity and potency for hSERT, compared to α -PVP. The addition of a 3,4-methylenedioxy group to pentedrone, forming pentylone, had no effect on the affinity at hDAT, but increased affinity and potency at hSERT 5-10 fold and decreased affinity at hNET four fold.
Although both compounds had the same order of potency at blocking the transporters (hDAT>hNET>hSERT) as α -PVP, the uptake potency ratios of hDAT to hSERT for pentedrone and pentylone are 51.1 and 4.9, reflecting their increased potency at hSERT (Table 2 ). For α -PVP, the uptake potency ratio of hDAT to hSERT is 2,893.
This article has not been copyedited and formatted. The final version may differ from this version. 
pentedrone and pentylone, the ratio is less than six at hDAT and hSERT and less than 13 at hNET ( Table 2 ), indicating that binding affinity is relatively predictive of uptake potency. This is also observed for cocaine and mazindol, which are pure uptake blockers at the transporters.
Thus, this pharmacological pattern suggests that these compounds may primarily interact with the transporters as uptake blockers. MCAT had much higher affinity at hDAT and hNET compared to hSERT and a rank order of potency for inhibition of uptake of hNET>hDAT>hSERT. Addition of 3-fluoro, 4-chloro, or 4-bromo substituents to MCAT had minimal effect on affinity or potency at hDAT (Table 1) .
However, the 4-chloro and 4-bromo moieties increased both affinity and potency at the hSERT, and decreased affinity and potency at the hNET, compared to MCAT. Compared to MCAT, ethylone and 4-MEC had similar affinity but lower potency (6-11 fold) at hDAT, increased affinity 15, and for MDAI the ratio was 11.9 for hDAT and greater than 200 for hSERT and hNET. For 4-MEC, 5-MeO-methylone and ethylone, the ratios for hDAT (3.1, <1.6 and 2.9) and hNET (17, 4, 13.2) were similar to that of the blockers, above, but for hSERT the ratios were much higher.
METH and MDMA are substrates at the transporters, and we and others have previously observed that substrates have higher potency at inhibition of uptake compared to affinity for radioligand binding sites Eshleman et al., 1999; Rothman et al., 2000) .
Thus, the results suggest that the compounds in this subset are substrates at some or all of the transporters. 1 6
efficacious. In contrast, the α -pyrrolidinophenones, pentedrone, pentylone, 4-MEC, 5-MeOmethylone and ethylone at concentrations ranging from 1 nM to 100 μ M (Fig 4A,4B ,5A, and 5B, Table 3 ) had little to no effect. Comparing the maximal drug-induced releases (Fig 4A and 4B , Fig   3B,4C ,4D,and 5C, Table 3 ). In contrast, the α -pyrrolidinophenones, pentedrone, and pentylone, had minimal releasing efficacy at concentrations ranging from 1 nM to 100 μ M (Fig 4D,5C and   5D ). Compared to the maximal release elicited by METH or PCA (Fig 4C,4D ,5C and 5D, Fig 4F,5E and 5F).
For compounds that stimulated release via the transporters, 3-F MCAT, 4-FA and MCAT had relative potency of hNET>hDAT> hSERT similar to that of METH, MDAI had relative potency of hNET>hSERT>hDAT similar to that of MDMA, and 4-MEC had relative potency of hNET>hSERT>>hDAT. Ethylone and 5-MeO-methylone stimulated release only via hSERT. 4-Br MCAT and 4-Cl MCAT had similar potencies for release at the three transporters. Because only a subset of the drugs had robust effects on release, it is difficult to establish structureactivity relationships across transporters.
As noted above, substrates, defined here as those compounds that elicit non-vesicular release via a transporter, have higher potency in uptake assays compared to their affinity for the [ 125 I]RTI-55 binding site. We queried whether there is a binding/uptake ratio above which we could predict with some assurance whether a compound is a substrate. Figure 6 shows the relationship between the affinity/potency ratios (listed in Table 2 ) and the percent maximal release for the 20 compounds reported here, six substituted methcathinones reported earlier , METH, MCAT, MDMA, S(+)amphetamine, (+)fenfluramine, DA, 5-HT and NE at the hDAT, hSERT and hNET. As shown, the relationship was generally hyperbolic, 1 9
Discussion
We have characterized the binding affinities and functional activities of 18 substituted cathinones and two structurally related compounds at the hDAT, hSERT and hNET.
For α -pyrrolidinophenones, increasing the chain length from 1 to 5 carbons (α-PPP to PV-8)
increased affinity for hDAT ~100 fold. These results, with increasing affinity and potency at hDAT correlating with increasing carbon chain length off the alpha carbon, are in agreement with Marusich et al. (2014) and Kolanos et al. (2015) , who found that the potencies for inhibition at DAT correlate with both the volume of the alpha-substituent and the lipophilic character. We further extended this finding to include hNET, with a ~17 fold increase in affinity from 1 to 3 carbons (α-PVP) and a correlation between affinity at hSERT and alpha-substituent chain length, although all of these compounds had very low affinity for hSERT. Rickli et al., (2015) indicated the same trend for 3,4-methylenedioxy substituted pyrovalerones. The n-pyrrolidino substituent on 4-MePPP is sterically repulsed by bulky side chains in SERT that are found in the orthosteric binding pocket as delineated by the Leu-T structural model, which may account for the low affinity of this entire series for SERT (Saha et al., 2015) . The pure transporter inhibitor activity of this group may be due to the n-pyrrolidino substituent, as Sandtner et al (2016) observed that interactions with critical aspartate residues of DAT and SERT are necessary for substrate activity and secondary or tertiary substitution on the nitrogen inhibits interaction with these residues. The high selectivity for hDAT over hSERT would suggest that these compounds may have high abuse liability, consistent with the ability of α -PBP and α -PVP to fully substitute for discriminative stimulus effects of both cocaine and METH and to produce conditioned place preference (Gatch et al., 2015a) . In contrast 4-MePPP fully substitutes only for METH, does not produce conditioned place preference (CPP) and in the current study had less selectivity for hDAT, all of which suggests a lower abuse liability as compared to other 2 0 discriminative stimulus effects due to the commonality of increased extracellular neurotransmitter following drug administration (Camp et al., 1994) .
Pentedrone and pentylone were two additional transporter inhibitors that had moderate affinity for hDAT. They produce long-lasting locomotor stimulant effects and fully substitute for discriminative stimulus effects of both cocaine and METH and pentedrone increases CPP in mice and is self-administered by rats (Gatch et al., 2015b; Hwang et al., 2015) . Both compounds may have abuse potential.
Differing from the expressing the hNET or hDAT, thereby elevating intracellular sodium to drive reverse transport (Galli et al., 1995; Sitte et al., 1998) . However, as HEK cells do not have synaptic vesicles (Hu et al., 2013) , release via vesicle fusion is not operational in our model system.
These potentially depolarizing transporter-mediated substrate-induced sodium currents (Sitte et al., 1998; Sonders et al., 1997) 2 1 exogenous substrate-induced sodium currents can put cells at risk, as (+)fenfluramine is associated with neuronal depletion of 5-HT and amphetamine can indirectly activate voltage-gated Ca 2+ channels (Cameron et al., 2015) . The substrates identified here, especially those that had efficacies similar to METH, may cause depolarization in neurons, as evidenced by the dose-dependent currents elicited by 4-MEC in Xenopus oocytes expressing hSERT (Saha et al., 2015) .
Diagnostic assays that assess whether a compound is a substrate include electrophysiological measurement of transporter-mediated currents and testing reverse transport under control and intracellular high-sodium conditions (Sitte and Freissmuth, 2015) . For example, evidence for substrate versus inhibitor action is the inward depolarizing current elicited by the substrates mephedrone and METH while blockers MDPV and cocaine elicit an outward hyperpolarizing current via DAT expressed in Xenopus oocytes (Cameron, et al., 2013) . The data in Figure 6 indicate that the binding affinity to uptake inhibition potency ratio is predictive for releasing efficacy, in this model of the transporters expressed in HEK cells with [ 125 I]RTI-55 as the radioligand. For example, the low ratios at hDAT and hNET and much higher ratios at hSERT for 4-MEC, 5-MeO-methylone and ethylone (Table 2) predict that these compounds would be blockers at hDAT and hNET but substrates at hSERT. As anticipated, these compounds were partially to fully efficacious releasers at hSERT (67-99%, Table 3 ), while none elicited release via hDAT and only 4-MEC minimally released (17%) via hNET. These results agree with Saha et al. (2015) , who reported that 4-MEC displays unique activity as a SERT substrate while being a DAT blocker. The binding-to-uptake ratios may be a quick metric to discriminate inhibitors from substrates, as they can be determined more quickly and easily than other methods such as the in vitro efflux methods reported here or the voltage-clamp current measures in Xenopus oocytes.
2
Drugs that are hDAT-selective produce more stimulant and abuse-related effects than substances with mixed action at hDAT and hSERT (Wee et al., 2005; Baumann et al., 2011) .
The halide substitutions at either the para or ortho position of MCAT decrease the hDAT:hSERT uptake selectivity as MCAT had 136 fold higher potency at hDAT while 3-F MCAT, 4-Cl MCAT and 4-Br MCAT had 60.3, 3.22 and 0.96 fold hDAT selectivity, respectively (Table 2) (Table 1 and   Table 3 ). These results are consistent with para halide MCAT substitutions decreasing the DAT:SERT release potencies from rat synaptosomes (Bonano et al., 2015) . MCAT robustly increases extracellular DA, while 4-F MCAT and 4-Cl MCAT robustly, and 4-Br MCAT modestly, increase both extracellular DA and 5-HT as measured by microdialysis in rats (Suyama et al., 2016) . The ratios of (in vivo) potencies to release DA and 5-HT correlate positively with maximal ICSS, a procedure that evaluates abuse potential, and negatively with the steric bulk of the compounds (Suyama et al., 2016) . Thus the abuse potential may decrease, while more MDMAlike empathogenic activity may increase, within this series.
With the in vitro model employed here, all substrates, except butylone at hSERT and 4-MEC at hNET, had 7-17 times lower potency on average at inducing release than at inhibition of uptake ( Figure 7 ). This finding may not apply to all model systems. Sandtner et al. (2016) reported higher potencies for release than for uptake for MDMA at the 3 transporters using rat brain synaptosomes whereas MDMA was 3, 3, and 18 fold less potent for release compared to uptake at hNET, hSERT, and hDAT respectively (Tables 2 and 3 
